Boston Scientific Cuts Guidance to 6.5–8%, Shares Drop Over 10%
BSX•Boston Scientific cut FY26 sales growth guidance to 6.5–8.0% (vs prior 10–11%) and Q2 guidance to 5–7% after slower WATCHMAN performance, EP share losses and urology headwinds, sending shares down over 10% to their lowest since October 2023. A Stifel Nicolaus analyst set a $75 target, implying 47% upside.
1. Guidance Revision Details
Boston Scientific lowered full-year FY26 net sales growth guidance to 6.5–8.0% organic (from 10.0–11.0%) and set Q2 guidance at 5–7%, reflecting cautious demand expectations after mixed procedure volumes.
2. Drivers of Weakness
CEO Mike Mahoney attributed the revision to three unanticipated factors: a slowdown in standalone WATCHMAN procedures with flat dollar growth through Q3, electrophysiology share losses as competitors launch new products, and urology softness from niche stone-treatment entrants and Axonics disruptions.
3. Analyst Outlook
Shares plunged over 10% to the lowest levels since October 2023, while Stifel Nicolaus raised its price target to $75, implying roughly 47% upside from the then-trading level near $51 and signaling confidence in a recovery.
